Mesenchymal stem cells have been applied to treat graft versus host disease as they have immunosuppressive ability and can overcome the major histocompatibility complex–histocompatibility barrier. The potential of allogeneic mesenchymal stem cells in treating systemic lupus erythematosus (SLE) was investigated in this study. MRL/lpr mice which can develop acquired SLE-like phenotypes were selected as an animal model. Mesenchymal stem cells obtained from green fluorescent protein-transgenic ICR mice were infused into MRL/lpr mice at either the early or late stage of disease. The dosage was 1 × 106/mice per infusion. Mice were stratified into six groups including negative controls and those receiving one, two, three, four or five doses at 2-weekly intervals. The phenotypes were monitored regularly. After treatment, the spleen CD3+CD4–CD8– T and CD19+ B cells of two-dose mesenchymal stem cell-treated mice were significantly lower than those of the phosphate-buffered saline control. In terms of reducing the severity of SLE such as hair loss, skin ulcers, proteinuria and anti-dsDNA level, mesenchymal stem cells given at the early stage responded better and mice receiving two doses of mesenchymal stem cells performed better than those receiving either a lower dose (one dose) or higher doses (three, four or five doses). In conclusion, early treatment and an optimal dose of mesenchymal stem cells can effectively suppress the murine SLE model.
PolymeriAGiannobileWVKaiglerD.Bone marrow stromal stem cells in tissue engineering and regenerative medicine. Hormone Metab Res2016;
48: 700–713.
2.
KrauseDS.Plasticity of marrow-derived stem cells. Gene Therapy2002;
9: 754–758.
3.
BrownCMcKeeCBakshiS, et al.
Mesenchymal stem cells: cell therapy and regeneration potential. J Tissue Engng Regenerat Med2019; 13: 1738–1755.
4.
Gazit Z, Pelled G, Sheyn D, Yakubovich DC, Gazit D. Mesenchymal stem cells. Principles of Regenerative Medicine 2019; 3: 205–218.
5.
Caplan AI. Mesenchymal stem cells in regenerative medicine. Principles of Regenerative Medicine 2019; 1: 219–227.
6.
ZhouWLinJZhaoK, et al.
Single-cell profiles and clinically useful properties of human mesenchymal stem cells of adipose and bone marrow origin.Am J Sports Med2019; 47: 1722–1733.
7.
FranquesaMMensahFKHuizingaR, et al.
Human adipose tissue‐derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells. Stem Cells2015;
33: 880–891.
8.
ZhaoQRenHHanZ.Mesenchymal stem cells: Immunomodulatory capability and clinical potential in immune diseases. J Cell Immunother2016;
2: 3–20.
9.
GaoFChiuSMMotanDAL, et al.
Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis2016;
7: e2062.
10.
AbomarayFMAl JumahMAKalionisB, et al.
Human chorionic villous mesenchymal stem cells modify the functions of human dendritic cells, and induce an anti-inflammatory phenotype in CD1+ dendritic cells. Stem Cell Rev Rep2015;
11: 423–441.
11.
MaOKFChanKH.Immunomodulation by mesenchymal stem cells: Interplay between mesenchymal stem cells and regulatory lymphocytes. World J Stem Cells2016;
8: 268.
FarinazzoAAngiariSTuranoE, et al.
Nanovesicles from adipose-derived mesenchymal stem cells inhibit T lymphocyte trafficking and ameliorate chronic experimental autoimmune encephalomyelitis. Sci Rep2018;
8: 7473.
14.
AndersonPGonzalez-ReyEO’ValleFMartinFOliverFJDelgadoM.Allogeneic adipose-derived mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by regulating self-reactive T cell responses and dendritic cell function. Stem Cells Int2017; 2017: 2389753.
15.
LiaoWPhamVLiuL, et al.
Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis. Biomaterials2016;
77: 87–97.
16.
KushidaTInabaMHishaH, et al.
Crucial role of donor‐derived stromal cells in successful treatment for intractable autoimmune diseases in MRL/lpr mice by BMT via portal vein. Stem Cells2001;
19: 226–235.
17.
CarlssonPOSchwarczEKorsgrenOLe BlancK.Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells.Diabetes2015;
64: 587–592.
18.
RekittkeNEAngMRawatDKhatriRLinnT.Regenerative therapy of type 1 diabetes mellitus: from pancreatic islet transplantation to mesenchymal stem cells. Stem Cells Int2016; 2016: 3764681.
19.
HashmiSAhmedMMuradMH, et al.
Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol2016;
3: e45–e52.
20.
ZhaoKLouRHuangF, et al.
Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant2015;
21: 97–104.
21.
DengWHanQLiaoLYouSDengHZhaoRC.Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol2005;
24: 458–463.
22.
KnightJSSubramanianVO’DellAA, et al.
Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis2015;
74: 2199–2206.
23.
SchaevitzLLimMDefensorE. Novel approaches to assess therapeutic efficacy in the MRL/lpr model of lupus. J Immunol 2017; 198: 213–219.
24.
JiaJLinXLinX, et al.
R/L, a double reporter mouse line that expresses luciferase gene upon Cre-mediated excision, followed by inactivation of mRFP expression. Genome2016;
59: 816–826.
25.
LewandoskiMMartinGR.Cre-mediated chromosome loss in mice. Nat Genet1997;
17: 223–225.
26.
YiYUANLingZHAONingMAZhuangYEZhenyu JiangCC.Up-regulated complement 3 production by Toll-like receptor 9/transforming growth factor-beta 1/complement 3 pathway in whole blood cells of lupus thrombocytopenia. Arch Rheumatol2017;
32: 275.
27.
BaoLHaasMKrausDM, et al.
Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol2003;
14: 670–679.
Le BlancKDaviesLC.MSCs – cells with many sides. Cytotherapy2018;
20: 273–278.
30.
ZhangLLuoQShuY, et al.
Transcriptomic landscape regulated by the 14 types of bone morphogenetic proteins (BMPs) in lineage commitment and differentiation of mesenchymal stem cells (MSCs). Genes Dis2019; 6: 258–275.
31.
WangLTTingCHYenML, et al.
Human mesenchymal stem cells (MSCs) for treatment towards immune-and inflammation-mediated diseases: review of current clinical trials. J Biomed Sci2016;
23: 76.
MariaATToupetKBonyC, et al.
Antifibrotic, antioxidant, and immunomodulatory effects of mesenchymal stem cells in HOCl‐induced systemic sclerosis. Arthritis Rheum2016;
68: 1013–1025.
34.
ZhangHLiangJTangX, et al.
Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis. Arthritis Res Ther2017;
19: 165.
35.
ZhouKZhangHJinO, et al.
Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol2008;
5: 417.
36.
SunLAkiyamaKZhangH, et al.
Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells2009;
27: 1421–1432.
37.
DotoliGMDe SantisGCOrellanaMD, et al.
Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation. Bone Marrow Transplant2017;
52: 859.
38.
YañezROviedoAAldeaMBuerenJALamanaML.Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp Cell Res2010;
316: 3109–3123.
39.
EspagnolleNBalguerieAArnaudESensebéLVarinA.CD54-mediated interaction with pro-inflammatory macrophages increases the immunosuppressive function of human mesenchymal stromal cells. Stem Cell Rep2017;
8: 961–976.
40.
NajarMRaicevicGFayyad-KazanHBronDToungouzMLagneauxL.Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells. Cytotherapy2016;
18: 160–171.
41.
AugelloATassoRNegrinSMCanceddaRPennesiG.Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen‐induced arthritis. Arthritis Rheum2007;
56: 1175–1186.
42.
CorcioneABenvenutoFFerrettiE, et al.
Human mesenchymal stem cells modulate B-cell functions. Blood2006;
107: 367–372.
43.
ZhangWYangMChenCF.Effect of bone marrow mesenchymal stem cells on T-cell subgroups. Zhongguo shi yan xue ye xue za zhi2008;
16: 863–866.
44.
LiWRenGHuangY, et al.
Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Different2012;
19: 1505.
45.
LeeHYHongIS.Double‐edged sword of mesenchymal stem cells: cancer‐promoting versus therapeutic potential. Cancer Sci2017;
108: 1939–1946.
46.
PennesiG.PD1-mediated mesenchymal stem cells immunemodulation: the two sides of the coin. Int Clin Pathol J2018;
6: 164–165.
47.
MohammadpourHPourfathollahAAZarifMNTahooriMT.TNF-α modulates the immunosuppressive effects of MSCs on dendritic cells and T cells. Int Immunopharmacol2015;
28: 1009–1017.
48.
TraggiaiEVolpiSSchenaF, et al.
Bone marrow‐derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells2008;
26: 562–569.
49.
ChanWKLauASYLiJCB, et al.
MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-γ challenge. Exp Hematol2008;
36: 1545–1555.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
